欢迎访问西亚试剂!
西亚试剂banner
西亚试剂banner
西亚试剂banner

当前位置:首页 > 新闻中心

西亚试剂:Biguanides suppress hepatic glucagon signalling by decreasi

发布时间:2025-05-22

Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP

Russell A. Miller, Qingwei Chu, Jianxin Xie, Marc Foretz, Benoit Viollet & Morris J. Birnbaum

Glucose production by the liver is essential for providing a substrate for the brain during fasting. The inability of insulin to suppress hepatic glucose output is a major aetiological factor in the hyperglycaemia of type-2 diabetes mellitus and other diseases of insulin resistance1, 2. For fifty years, one of the few classes of therapeutics effective in reducing glucose production has been the biguanides, which include phenformin and metformin, the latter the most frequently prescribed drug for type-2 diabetes3. Nonetheless, the mechanism of action of biguanides remains imperfectly understood. The suggestion a decade ago that metformin reduces glucose synthesis through activation of the enzyme AMP-activated protein kinase (AMPK) has recently been challenged by genetic loss-of-function experiments4. Here we provide a novel mechanism by which metformin antagonizes the action of glucagon, thus reducing fasting glucose levels. In mouse hepatocytes, metformin leads to the accumulation of AMP and related nucleotides, which inhibit adenylate cyclase, reduce levels of cyclic AMP and protein kinase A (PKA) activity, abrogate phosphorylation of critical protein targets of PKA, and block glucagon-dependent glucose output from hepatocytes. These data support a mechanism of action for metformin involving antagonism of glucagon, and suggest an approach for the development of antidiabetic drugs.

 

上一篇:西亚试剂:使用生物条形码对鱼等食品进行产地到餐桌的全程追踪
下一篇:西亚试剂:Rqc2p and 60S ribosomal subunits mediate mRNA-independent e
版权所有:山东西亚化学有限公司

鲁ICP备20015914号-4